Skip to main content

oncology_research

Inhibrx to Reveal Phase 2 HexAgon Data on INBRX-106 Sept. 8

Inhibrx to Reveal Phase 2 HexAgon Data on INBRX-106 Sept. 8

San Diego – September 09, 2026 -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) will webcast primary endpoint results from the randomized, controlled Phase 2 portion of its HexAgon study on Tuesday, September 8, 2026 at 5:00 a.m. Pacific Time.

Phase 2 data will compare INBRX-106 combination therapy against pembrolizumab alone

The study evaluates INBRX-106, a hexavalent OX40 agonist, combined with pembrolizumab against pembrolizumab monotherapy as a control arm. The trial enrolled first-line, treatment-naïve patients with PD-L1 positive (CPS ≥ 20) metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).

IDEAYA Sets Phase 3 Design for IDE849 After FDA Type C Meeting

IDEAYA Sets Phase 3 Design for IDE849 After FDA Type C Meeting

SOUTH SAN FRANCISCO, Calif. -- September 01, 2026 -- IDEAYA Biosciences said its FDA Type C meeting on IDE849, a DLL3-targeting antibody drug conjugate, produced agreement on a Phase 3 registrational trial design for extensive stage small cell lung cancer (ES-SCLC). The Nasdaq-listed company (IDYA) plans to enroll roughly 400 patients who have already received tarlatamab, randomizing them 1:1 between IDE849 monotherapy and an investigator's choice control arm of topotecan and amrubicin. IDEAYA is targeting trial initiation by year-end 2026.